dipyridamole has been researched along with Diabetic Retinopathy in 12 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| ", aspirin alone (330 mg 3 times daily) or in combination with dipyridamole (75 mg 3 times daily), was tested versus placebo in 475 patients with early diabetic retinopathy." | 9.06 | Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. ( , 1989) |
| "A description is given of the ophthalmological protocol of the DAMAD (aspirin and dipyridamole + Aspirin) controlled clinical trial in diabetic retinopathy." | 9.05 | [Controlled clinical trial of the effect of aspirin and aspirin + dipyridamole on the development of diabetic retinopathy. II. Ophthalmologic protocol]. ( , 1982) |
| ", aspirin alone (330 mg 3 times daily) or in combination with dipyridamole (75 mg 3 times daily), was tested versus placebo in 475 patients with early diabetic retinopathy." | 5.06 | Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. ( , 1989) |
| "To assess coronary blood flow velocity in young patients with type 1 DM using transoesophageal Doppler echocardiography with dipyridamole and to analyse the possible relationship between the impairment of coronary flow and retinopathy as well as microalbuminuria." | 3.74 | Association between retinopathy, microalbuminuria and coronary perfusion in young patients with type 1 diabetes mellitus. ( Biegalski, W; Dankowski, R; Kandziora, M; Michalski, M; Naskret, D; Poprawski, K; Wierzchowiecki, M, 2008) |
| "A total of 21 men with Type 1 diabetes were investigated, including 9 men with background retinopathy and 12 men without retinopathy." | 2.71 | Diabetic background retinopathy is associated with impaired coronary vasoreactivity in people with Type 1 diabetes. ( Janatuinen, T; Knuuti, J; Nuutila, P; Raitakari, OT; Rönnemaa, T; Sundell, J; Toikka, J, 2004) |
| " Platelet survival in 27 insulin-dependent diabetic patients with severe retinopathy was studied in a double-blind cross-over trial using placebo, aspirin (990 mg/day) and a combination of dipyridamole (225 mg/day) with aspirin at two dosage levels (330 mg and 990 mg/day)." | 2.65 | Aspirin, dipyridamole and platelet survival in patients with diabetes mellitus. ( McNicol, GP; Paton, RC; Tindall, H, 1982) |
| " The effect is increased significantly, especially in the sensory sphere (tactile, temperature and pain sensitivity), when the drug is used in combination with curantyl in dosage 50 mg twice daily for 3 months." | 1.35 | [The use of dipyridamole (curantyl) in combination with alpha-lipoic acid in the treatment of diabetic neuropathy with retinopathy]. ( Al-Zamil, MKh, 2008) |
| "The patients with IDDM had normal exercise echocardiography and autonomic nervous function tests." | 1.30 | Coronary flow reserve is reduced in young men with IDDM. ( Iida, H; Knuuti, J; Koskinen, PJ; Laine, HK; Lehtimäki, TJ; Nuutila, P; Pitkänen, OP; Raitakari, OT; Rönnemaa, T; Takala, T; Viikari, JS, 1998) |
| "Treatment with dipyridamole, mopidamol, and RA-642 caused 2." | 1.29 | The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus. ( De La Cruz, JP; García Campos, J; Mérida, F; Moreno, A; Sánchez de la Cuesta, F, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (50.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Zamil, MKh | 1 |
| Taskiran, M | 1 |
| Fritz-Hansen, T | 1 |
| Rasmussen, V | 1 |
| Larsson, HB | 1 |
| Hilsted, J | 1 |
| Sundell, J | 1 |
| Janatuinen, T | 1 |
| Rönnemaa, T | 2 |
| Raitakari, OT | 2 |
| Toikka, J | 1 |
| Nuutila, P | 2 |
| Knuuti, J | 2 |
| Dankowski, R | 1 |
| Wierzchowiecki, M | 1 |
| Naskret, D | 1 |
| Michalski, M | 1 |
| Kandziora, M | 1 |
| Biegalski, W | 1 |
| Poprawski, K | 1 |
| Saldan, IR | 1 |
| Tindall, H | 1 |
| Paton, RC | 1 |
| McNicol, GP | 1 |
| De La Cruz, JP | 1 |
| Moreno, A | 1 |
| Mérida, F | 1 |
| García Campos, J | 1 |
| Sánchez de la Cuesta, F | 1 |
| Pitkänen, OP | 1 |
| Koskinen, PJ | 1 |
| Iida, H | 1 |
| Lehtimäki, TJ | 1 |
| Laine, HK | 1 |
| Takala, T | 1 |
| Viikari, JS | 1 |
| Howard-Williams, JR | 1 |
| Siegel, MJ | 1 |
| Podos, SM | 1 |
| Brown, V | 1 |
5 trials available for dipyridamole and Diabetic Retinopathy
| Article | Year |
|---|---|
Diabetic background retinopathy is associated with impaired coronary vasoreactivity in people with Type 1 diabetes.
Topics: Adult; Autonomic Nervous System; Blood Pressure; Coronary Circulation; Coronary Vessels; Diabetes Me | 2004 |
[Controlled clinical trial of the effect of aspirin and aspirin + dipyridamole on the development of diabetic retinopathy. II. Ophthalmologic protocol].
Topics: Aspirin; Clinical Trials as Topic; Diabetic Retinopathy; Dipyridamole; Drug Therapy, Combination; Fl | 1982 |
Aspirin, dipyridamole and platelet survival in patients with diabetes mellitus.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cell Survival; Clinical Trials as Topic; Diabetic Retinopathy | 1982 |
[Controlled clinical trial of the effect of aspirin and aspirin + dipyridamole on the development of diabetic retinopathy. I. General protocol. From the DAMAD Study Group (author's transl)].
Topics: Adolescent; Adult; Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Diabetic Retinopathy; D | 1982 |
Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group.
Topics: Adult; Aspirin; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellit | 1989 |
7 other studies available for dipyridamole and Diabetic Retinopathy
| Article | Year |
|---|---|
[The use of dipyridamole (curantyl) in combination with alpha-lipoic acid in the treatment of diabetic neuropathy with retinopathy].
Topics: Adult; Aged; Antioxidants; Diabetic Neuropathies; Diabetic Retinopathy; Dipyridamole; Drug Therapy, | 2008 |
Decreased myocardial perfusion reserve in diabetic autonomic neuropathy.
Topics: Adult; Age of Onset; Albuminuria; Blood Pressure; Diabetic Neuropathies; Diabetic Retinopathy; Dipyr | 2002 |
Association between retinopathy, microalbuminuria and coronary perfusion in young patients with type 1 diabetes mellitus.
Topics: Adolescent; Adult; Albuminuria; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Diabete | 2008 |
[Use of disaggregants in treating diabetic retinopathy].
Topics: Ascorbic Acid; Aspirin; Calcium Dobesilate; Diabetic Angiopathies; Diabetic Retinopathy; Dipyridamol | 1984 |
The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dipyridamole; Epopros | 1996 |
Coronary flow reserve is reduced in young men with IDDM.
Topics: Adult; Autonomic Nervous System; Blood Glucose; Coronary Circulation; Coronary Disease; Diabetes Mel | 1998 |
Alteration of the blood-retinal barrier by dipyridamole.
Topics: Blood Physiological Phenomena; Diabetic Retinopathy; Dipyridamole; Fluorescein Angiography; Humans; | 1986 |